[
    [
        {
            "time": "",
            "original_text": "3天3笔定增，高瓴开始狙击港股？2020年百亿医疗定增折戟九成？ 再融资异常",
            "features": {
                "keywords": [
                    "定增",
                    "高瓴",
                    "港股",
                    "医疗",
                    "再融资"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医疗",
                    "金融"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "3天3笔定增，高瓴开始狙击港股？2020年百亿医疗定增折戟九成？ 再融资异常",
                "Correlation": 8,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 6,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "【医药】第四批集采报价落幕，规模化仿制药平台或长存――医药行业点评——中性",
            "features": {
                "keywords": [
                    "医药",
                    "集采",
                    "仿制药",
                    "行业点评"
                ],
                "sentiment_score": 0.2,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "【医药】第四批集采报价落幕，规模化仿制药平台或长存――医药行业点评——中性",
                "Correlation": 7,
                "Sentiment": 5,
                "Importance": 8,
                "Impact": 6,
                "Duration": 8,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "医药行业重大事项点评：第四批带量采购拟中标结果产生 降价幅度符合预期",
            "features": {
                "keywords": [
                    "医药",
                    "带量采购",
                    "降价",
                    "中标"
                ],
                "sentiment_score": 0.4,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药行业重大事项点评：第四批带量采购拟中标结果产生 降价幅度符合预期",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 9,
                "Impact": 8,
                "Duration": 9,
                "Entity_Density": 7,
                "Market_Scope": 9,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        }
    ]
]